Regarding CCSVI: Is Blinding the Key?  by Zamboni, P. et al.
at SciVerse ScienceDirect
European Journal of Vascular and Endovascular Surgery 43 (2012) 126Contents lists availableEuropean Journal of Vascular and Endovascular Surgery
journal homepage: www.ejves.comCorrespondence
Regarding CCSVI: Is Blinding the Key?The invited commentaryofMayer and Ziemann aboutour original
article on venous angioplasty in chronic cerebrospinal venous insufﬁ-
ciency in multiple sclerosis patients (CCSVI-MS)1,2 raises several
important questions in relation to the methodology of our study.
The authors criticise our preliminary ﬁndings and doubt the
blinded assessment of the reported magnetic resonance imaging
(MRI) measures that represented the primary outcome measures
in this study, as generally accepted in pilot safety and preliminary
efﬁcacy trials in MS. We believe that we did not need to specify
how blinding of the MRI analysis was achieved, as hundreds of arti-
cleshave alreadyestablished that aspartof standardpractice.Never-
theless, we convey that theMRI analysis in the CCSVI-MS study was
performed fully blinded, as are all phase I, II, III and IV trials calcu-
lated at the Buffalo Neuroimaging Analysis Center (BNAC), Buffalo,
NY, USA. BNAC has been involved as an MRI analysis centre in
manyMSclinical trials that includedover 500 sites around theworld
in 55 countries. We considered describing how the MRI Digital
Imaging andCommunications inMedicine (DICOM)ﬁles are blinded
and how theworkload is distributed, but the authors are free to visit
our centre and examine our internal standard operating procedures
(SOPs) that have been accepted as appropriate following standard
audits by government and industry agencies. BNAC is one of the
most important centres for blinded MRI analysis for MS trials in
the North America and such assessment is routine practice.
By contrast, ourMRI study results are of interest and not affected
by the placebo effect or the need for a sham arm. For instance, the
reduction of 23% in T2 lesion volume (LV) in the immediate treated
arm as compared to the 8% increase in the delayed control arm in
the ﬁrst 6 months of the study is probably less likely to be affected
by a placebo effect. At least such an effect of a placebo on T2-LV
decrease was not observed in previous MS clinical trials. Moreover,
the 60% reduction in brain volume in the treated immediate
group compared with the delayed treatment arm over 6 months
further testiﬁes to a potential anti-inﬂammatory effect of venous
angioplasty in CCSVI-MS. Although preliminary, these data suggest
that venous angioplasty in CCSVI-MS may have potential anti-
inﬂammatory effects in patients with MS.
Another argument is related to the need of double-blinded
treatment trials that will use a sham arm to demonstrate the poten-1078-5884/$ – see front matter  2011 Published by Elsevier Ltd on behalf of European
doi:10.1016/j.ejvs.2011.10.012tial effect of angioplasty in MS patients. Our study was not only
designed to test clinical and MRI efﬁcacy, but also to provide
preliminary safety results and experience, based on which further
placebo-controlled phase I, II and III trials can be better designed.3
In fact, such double-blinded, placebo-controlled trials are under
way in our centres.4,5References
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